Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients

Leonidas C. Platanias, Carole B. Miller, Rosemarie Mick, Ronald D. Hart, Howard Ozer, Jan Marie McEvilly, Richard J. Jones, Mark J. Ratain

Research output: Contribution to journalArticle

Abstract

Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days each week. Of 30 patients, 15 (50%) had a greater than 10% increase of their hemoglobin (Hb) values and were considered responders. At the two highest dose levels, 11 of 13 patients (85%) responded. In the 15 responding patients, the mean Hb level increased by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration. Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.

Original languageEnglish (US)
Pages (from-to)2021-2026
Number of pages6
JournalJournal of Clinical Oncology
Volume9
Issue number11
DOIs
StatePublished - Nov 1991
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Platanias, L. C., Miller, C. B., Mick, R., Hart, R. D., Ozer, H., McEvilly, J. M., Jones, R. J., & Ratain, M. J. (1991). Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. Journal of Clinical Oncology, 9(11), 2021-2026. https://doi.org/10.1200/JCO.1991.9.11.2021